Isis Pharmaceuticals Inc. (ISIS) Has Climbed To A New High For...

Isis Pharmaceuticals Inc. (ISIS) Has Climbed To A New High For The Year


(RTTNews.com) - Isis Pharmaceuticals Inc. (ISIS) announced Saturday that data from a Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, showed that three patients achieved substantial reductions in triglycerides with all three patients achieving a triglyceride level below 500 mg/dL.

Isis Pharmaceuticals gapped up Monday and has continued to rise in early trade. Shares are now up 3.30 at $39.36 and have climbed to a new high for the year.

For comments and feedback: contact [email protected]

http://www.rttnews.com